Formulation: 40 mM Tris-HCl, pH 8.0, with 110 mM sodium chloride, 2.2 mM potassium chloride, 20% glycerol, and variable glutathione
Purity: ≥80% estimated by SDS-PAGE
Shelf life (days): 180
Notes: Histone-lysine N-methyltransferase SETDB1 is a member of the SUV39-related protein lysine methyltransferase (PKMT) family and is involved in epigenetic regulation.{65503} It is composed of an N-terminal domain that contains two nuclear export signals, two nuclear localization signals, three tudor domains that facilitate complexation with transcriptional regulators, and a methyl-CpG-binding domain (MBD), which binds to DNA, and a C-terminal domain that contains pre-SET, SET, and post-SET domains, which are responsible for the methyltransferase activity. Alternative splicing of SETDB1 produces two shorter isoforms with either a truncated post-SET domain, which retains enzymatic activity, or a full C-terminal truncation, which lacks enzymatic activity. SETDB1 is ubiquitously expressed and localizes to the nucleus and cytoplasm.{65504,65505} It induces gene silencing by di- and trimethylation of histone H3 at lysine 9 (H3K9) using S-adenosylmethionine as the methyl donor and regulates various cellular processes, including cell division and proliferation, retroelement suppression, immune cell function, X chromosome inactivation, nervous system development, and the formation of promyelocytic leukemia nuclear bodies (PML-NBs).{65503} Overexpression of SETDB1 increases the number of colon cancer cells in the S and G2/M phases in vitro and promotes tumor growth in vivo.{65506} Increased SETDB1 protein levels are associated with schizophrenia, and mutations in SETDB1 have been found in patients with inflammatory bowel disease (IBD).{65503} Cayman’s SETDB1 (human, recombinant) protein can be used for enzyme activity assays.
English
Deutsch
